CN107105695A - 具有增强的抗氧化性的海洋卵磷脂制剂 - Google Patents
具有增强的抗氧化性的海洋卵磷脂制剂 Download PDFInfo
- Publication number
- CN107105695A CN107105695A CN201580066582.6A CN201580066582A CN107105695A CN 107105695 A CN107105695 A CN 107105695A CN 201580066582 A CN201580066582 A CN 201580066582A CN 107105695 A CN107105695 A CN 107105695A
- Authority
- CN
- China
- Prior art keywords
- ocean
- lecithin
- preparation
- oil
- exogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 title claims abstract description 137
- 229940067606 lecithin Drugs 0.000 title claims abstract description 137
- 239000000787 lecithin Substances 0.000 title claims abstract description 137
- 235000010445 lecithin Nutrition 0.000 title claims abstract description 137
- 238000002360 preparation method Methods 0.000 title claims abstract description 106
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 230000003647 oxidation Effects 0.000 claims abstract description 15
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 57
- 239000003921 oil Substances 0.000 claims description 47
- 235000019198 oils Nutrition 0.000 claims description 47
- 239000003960 organic solvent Substances 0.000 claims description 34
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 32
- 229930003799 tocopherol Natural products 0.000 claims description 27
- 239000011732 tocopherol Substances 0.000 claims description 27
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 25
- 235000010384 tocopherol Nutrition 0.000 claims description 25
- 229960001295 tocopherol Drugs 0.000 claims description 25
- 230000003078 antioxidant effect Effects 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000002028 Biomass Substances 0.000 claims description 21
- 239000007791 liquid phase Substances 0.000 claims description 21
- 210000002784 stomach Anatomy 0.000 claims description 21
- 241000239366 Euphausiacea Species 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 10
- 235000021323 fish oil Nutrition 0.000 claims description 9
- 230000003859 lipid peroxidation Effects 0.000 claims description 9
- 241000251468 Actinopterygii Species 0.000 claims description 8
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 235000013793 astaxanthin Nutrition 0.000 claims description 8
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 8
- 229940022405 astaxanthin Drugs 0.000 claims description 8
- 239000001168 astaxanthin Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 238000005238 degreasing Methods 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000001149 cognitive effect Effects 0.000 claims description 6
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 150000002978 peroxides Chemical class 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 241000195493 Cryptophyta Species 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 238000007737 ion beam deposition Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- 239000003791 organic solvent mixture Substances 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 235000019149 tocopherols Nutrition 0.000 claims 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims 2
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000001175 peptic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 10
- 230000009467 reduction Effects 0.000 abstract description 7
- 235000013376 functional food Nutrition 0.000 abstract description 6
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 230000035764 nutrition Effects 0.000 abstract description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 239000012074 organic phase Substances 0.000 description 20
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 20
- 229940106134 krill oil Drugs 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 150000002432 hydroperoxides Chemical class 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- -1 Lipid hydroperoxide Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000011877 solvent mixture Substances 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000005484 gravity Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 6
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 230000003064 anti-oxidating effect Effects 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 235000012970 cakes Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 229930014669 anthocyanidin Natural products 0.000 description 4
- 235000008758 anthocyanidins Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 208000037998 chronic venous disease Diseases 0.000 description 4
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 235000019733 Fish meal Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 3
- 235000008452 baby food Nutrition 0.000 description 3
- 229940066595 beta tocopherol Drugs 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 235000007336 cyanidin Nutrition 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000004467 fishmeal Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000003617 peroxidasic effect Effects 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 239000011590 β-tocopherol Substances 0.000 description 3
- 235000007680 β-tocopherol Nutrition 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 2
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 2
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 241001529744 Origanum Species 0.000 description 2
- 235000011203 Origanum Nutrition 0.000 description 2
- 229920001991 Proanthocyanidin Polymers 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 235000009962 acacetin Nutrition 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000015838 chrysin Nutrition 0.000 description 2
- 229940043370 chrysin Drugs 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000007242 delphinidin Nutrition 0.000 description 2
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 description 2
- 235000010389 delta-tocopherol Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical compound OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 description 2
- 229930003949 flavanone Natural products 0.000 description 2
- 235000011981 flavanones Nutrition 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 235000013611 frozen food Nutrition 0.000 description 2
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- OKISBDHRUPZLOC-UHFFFAOYSA-N gallin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C(O)=C2OC2=C(O)C(O)=CC=C21 OKISBDHRUPZLOC-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000009584 malvidin Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013310 margarine Nutrition 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000020166 milkshake Nutrition 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 description 2
- 235000006251 pelargonidin Nutrition 0.000 description 2
- XVFMGWDSJLBXDZ-UHFFFAOYSA-O pelargonidin Chemical compound C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 XVFMGWDSJLBXDZ-UHFFFAOYSA-O 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- MYMGKIQXYXSRIJ-UHFFFAOYSA-N rhamnacene Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(OC)=C1 MYMGKIQXYXSRIJ-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000014620 theaflavin Nutrition 0.000 description 2
- 229940026509 theaflavin Drugs 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000002446 δ-tocopherol Substances 0.000 description 2
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- PADQINQHPQKXNL-LSDHHAIUSA-N (+)-dihydrokaempferol Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C=C1 PADQINQHPQKXNL-LSDHHAIUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- SBZWTSHAFILOTE-SOUVJXGZSA-N (2R,3S,4S)-leucocyanidin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3[C@H](O)[C@@H]2O)=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-SOUVJXGZSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- SEBFKMXJBCUCAI-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-WAABAYLZSA-N 0.000 description 1
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- BBZPLMOSAFDXCF-UHFFFAOYSA-N C1(C(C=CC=C1)C)(C)O.[Fe] Chemical group C1(C(C=CC=C1)C)(C)O.[Fe] BBZPLMOSAFDXCF-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 240000001549 Ipomoea eriocarpa Species 0.000 description 1
- 235000005146 Ipomoea eriocarpa Nutrition 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- HMXJLDJMSRBOCV-UHFFFAOYSA-N Leucocyanidin Natural products OC1C(OC2C(O)C(Oc3cc(O)cc(O)c23)c4ccc(O)c(O)c4)c5c(O)cc(O)cc5OC1c6ccc(O)c(O)c6 HMXJLDJMSRBOCV-UHFFFAOYSA-N 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- KOXRJHMEFYNYME-VBKZILBWSA-N Theaflagallin Natural products C1=C2C=C(O)C(O)=C(O)C2=C(O)C(=O)C=C1[C@H]1OC2=CC(O)=CC(O)=C2C[C@@H]1O KOXRJHMEFYNYME-VBKZILBWSA-N 0.000 description 1
- 229930185110 Theasinensin Natural products 0.000 description 1
- YUULFXAQUWEYNP-UHFFFAOYSA-N Theasinensin D Natural products C=1C(O)=C(O)C(O)=C(C=2C(=CC(O)=C(O)C=2O)C2C(CC3=C(O)C=C(O)C=C3O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)C=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 YUULFXAQUWEYNP-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- RAYJUFCFJUVJBB-UHFFFAOYSA-N dihydrokaempferol Natural products OC1Oc2c(O)cc(O)cc2C(=O)C1c3ccc(O)cc3 RAYJUFCFJUVJBB-UHFFFAOYSA-N 0.000 description 1
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000003778 fat substitute Substances 0.000 description 1
- 235000013341 fat substitute Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 230000009567 fermentative growth Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010732 heat treating oil Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- SBZWTSHAFILOTE-UHFFFAOYSA-N leucocianidol Natural products OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-UHFFFAOYSA-N 0.000 description 1
- 229940086558 leucocyanidin Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- KQFUXLQBMQGNRT-UHFFFAOYSA-N pachypodol Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(OC)=C1 KQFUXLQBMQGNRT-UHFFFAOYSA-N 0.000 description 1
- UOJMTSCORVQOHS-UHFFFAOYSA-N pachypodol Natural products COc1cc(ccc1O)C2=C(C)C(=O)c3c(O)cc(C)cc3O2 UOJMTSCORVQOHS-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XFDQJKDGGOEYPI-UHFFFAOYSA-O peonidin Chemical compound C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 XFDQJKDGGOEYPI-UHFFFAOYSA-O 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- 235000006404 peonidin Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- AFOLOMGWVXKIQL-UHFFFAOYSA-O petunidin Chemical compound OC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 AFOLOMGWVXKIQL-UHFFFAOYSA-O 0.000 description 1
- 229930015717 petunidin Natural products 0.000 description 1
- 235000006384 petunidin Nutrition 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
- C11B5/0021—Preserving by using additives, e.g. anti-oxidants containing oxygen
- C11B5/0028—Carboxylic acids; Their derivates
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
- C11B5/0021—Preserving by using additives, e.g. anti-oxidants containing oxygen
- C11B5/0035—Phenols; Their halogenated and aminated derivates, their salts, their esters with carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明提供海洋卵磷脂制剂,其包括海洋卵磷脂和一种或多种外源性抗氧化剂。还提供了包含海洋卵磷脂制剂的营养、药物或保健组合物或功能食品或医学食品。还提供了制备海洋卵磷脂制剂的方法。还提供了治疗或预防疾病或病症的方法,所述方法包括向受试者施用治疗有效量的海洋卵磷脂制剂。还提供降低施用于需要海洋卵磷脂的受试者的组合物的氧化状态的方法,所述方法包括施用所述组合物并将有效量的海洋卵磷脂制剂共同施用于需要海洋卵磷脂的受试者。
Description
发明领域
本发明涉及具有增强的抗氧化性的海洋卵磷脂制剂。
背景技术
流行病学研究和临床研究已经将各种健康益处与鱼和海产品的消耗相关联。归因于长链n-3多不饱和脂肪酸(LC-PUFA)的存在的这些正面健康结果包括降低心血管疾病(CVD)(Hu和Willett 2002)、抗炎性质(Calder 2004)、关节炎(Deutsch 2007)、经前期综合征等的风险。
LC-PUFA对脂质过氧化反应非常敏感,并且可以在整个加工过程中以及随后的包封或制剂中迅速氧化(Hamilton 1998;Undeland等人1998;Baik等人2004)。
脂质过氧化是指脂质的氧化降解。它是一种自由基介导的反应链,一旦启动,导致多不饱和脂质的氧化变质。这些反应可以由许多有毒产物包括氢过氧化物(LOOH)和醛引发或增强。可以通过测量脂质过氧化产物如LOOH和丙二醛(MDA)来监测脂质过氧化过程的进展。
初级过氧化产物是氢过氧化物,其中双键可能已经移动和/或改变构型。这些产物可以在结构上重新排列并转化成二级过氧化产物,通过裂解产生更小的分子或通过二聚合产生更大的分子。脂质氢过氧化物是不稳定的,它们的断裂产生诸如MDA的产物。
MDA是三碳低分子量醛,是脂质氧化的二级产物之一,对健康有害,并且是由含有至少三个双键的脂肪酸的氧化过程形成的。虽然MDA不是脂质过氧化反应的化学计量标记,但与LOOH积累相比,其积累反映了脂质过氧化反应过程的强度。这些物种以及一些其他物质的测量可以评估不同阶段的氧化途径,提供该动态过程的详细信息。
脂质过氧化是一个关键的降解过程,负责降低海洋ω-3油的质量,包括气味、颜料和质地的变化。脂质过氧化还负责产生大量的细胞毒性化合物(Addis1986;Kubow 1992)。此外,已经表明,氧化的海洋ω-3油可能具有受损的功效,导致补充有效性的变化(Turner2006)。重要的是,几项研究表明,消耗含有脂质氧化终产物的膳食或油后血浆过氧化脂质标志物增加,表明氧化脂质具有被肠吸收的能力。Strapans和同事(1994,1999)表明,膳食氧化脂质是人血清乳糜微粒中氧化脂质的来源。Naruszewicz发现,热处理油的消耗导致脂质过氧化物的餐后血浆水平显著增加(Naruszewicz等人1987)。
除了磷脂(主要是磷脂酰胆碱)结合的LC-PUFA之外,海洋卵磷脂如磷虾油含有天然抗氧化剂(虾青素)。已知这些卵磷脂在保质期内是稳定的,这可能是由于天然抗氧化剂的存在。本申请的发明人发现,在其保质期内显示出稳定性的海洋卵磷脂具有最小的过氧化作用,在胃肠道条件下易受脂质过氧化的影响。发明人能够通过向具有优选低三甲胺N-氧化物(TMAO)水平的海洋卵磷脂添加某些抗氧化剂来解决这个问题。
发明内容
本发明提供了包含海洋卵磷脂和一种或多种外源性抗氧化剂的海洋卵磷脂制剂,其中所述制剂具有的所述一种或多种外源性抗氧化剂的浓度为10mg/kg或更多。有时,所述一种或多种外源性抗氧化剂的浓度为100mg/kg或更多,有时为500mg/kg或更多,有时为1000mg/kg或更多,有时为1200mg/kg或更多,有时为1400mg/kg或更多,有时为1600mg/kg或更多,有时为2000mg/kg或更多,有时为2500mg/kg或更多,有时为3000mg/kg或更多,有时为4000mg/kg或更多。
优选地,所述一种或多种外源性抗氧化剂以有效减少胃肠道条件中的脂质过氧化的量提供。优选地,海洋卵磷脂来自磷虾或鱼源。优选地,所述一种或多种外源性抗氧化剂包含至少一种生育酚。有时,所述一种或多种外源性抗氧化剂包含两种或更多种不同生育酚(例如α-生育酚、β-生育酚、γ-生育酚和δ-生育酚)的混合物。
在本发明的某些其它非限制性实施方案中,所述制剂具有大于700mg/kg的内源性钙浓度。在本发明的某些其它非限制性实施方案中,所述制剂具有大于500mg/kg的内源性镁浓度。在本发明的某些其它非限制性实施方案中,所述制剂具有至少2%(w/w)的磷脂。在本发明的某些其它非限制性实施方案中,所述制剂具有至少3%(w/w)的EPA和至少2%(w/w)的DHA。
在本发明的某些其它非限制性实施方案中,所述制剂具有25mgN/100g或更少的三甲胺N-氧化物(TMAO)浓度。有时,所述TMAO浓度为15mgN/100g或更少,有时为10mgN/100g或更少,有时为7mgN/100g或更少,有时为5mgN/100g或更少,有时为3mgN/100g或更少,和有时为1mgN/100g或更少。在本发明的某些其它非限制性实施方案中,所述制剂具有5mgN/100g或更少的三甲胺(TMA)浓度。在本发明的某些实施方案中,在40℃或以下储存3个月,优选6个月后,磷虾油具有5mgN/100g或更少的TMA。在本发明的某些其它非限制性实施方案中,所述制剂具有少于1200mg/kg的钠浓度。在本发明的某些其它非限制性实施方案中,所述制剂具有的游离胆碱浓度小于450mg/kg和/或甜菜碱浓度低于1000mg/kg和/或总氨基酸浓度小于0.3g/100g。
在本发明的某些其它非限制性实施方案中,在胃模型中孵育制剂180分钟后,所述制剂中丙二醛(MDA)水平不超过6μmol/g,有时为4μmol/g,有时为2μmol/g,有时为0μmol/g。
在本发明的某些其它非限制性实施方案中,在胃模型中孵育制剂180分钟后,所述制剂中氢过氧化物(LOOH)水平不超过10μmol/g,有时为6μmol/g,有时为4μmol/g,有时为2μmol/g,和有时为0μmol/g。
在本发明的某些其它非限制性实施方案中,在胃模型中孵育制剂180分钟后,磷脂、甘油三酯、脂肪酸、虾青素或任何其它活性成分的水平为孵育前其初始值的80%或更高。优选地,其水平为孵育前其初始值的85%或更高,更优选90%或更高,进一步优选97%或更高,最优选99%或更高。
在本发明的某些其它非限制性实施方案中,所述制剂还包含油。优选地,所述油是鱼油、藻油、植物油或其组合。更优选地,所述油包含至少一种ω-3脂肪酸,其中所述油具有的所述至少一种ω-3脂肪酸的浓度为25%(w/w)或更高。
本发明还提供了包含上述任一种制剂的营养、药物或保健组合物或功能食品或医疗食品。
本发明还提供了制备根据本发明的海洋卵磷脂制剂的方法,包括:将海洋生物质与至少一种有机溶剂混合;将所述至少一种有机溶剂与脱脂生物质分离,得到含有所述至少一种有机溶剂和海洋卵磷脂的液相;从液相中蒸发出所述至少一种有机溶剂;获得海洋卵磷脂;并在该过程的任何阶段加入一种或多种外源性抗氧化剂。
本发明还提供了制备根据本发明的海洋卵磷脂制剂的方法,包括:在生物质的制备过程中加入一种或多种外源性抗氧化剂;将海洋生物质与至少一种有机溶剂混合;将所述至少一种有机溶剂与脱脂生物质分离,得到含有所述至少一种有机溶剂和海洋卵磷脂的液相;从液相中蒸发出所述至少一种有机溶剂并获得海洋卵磷脂。
有时,所描述的方法中的每一个可以进一步包括至少一个用水洗涤的步骤。任选地,当进行所述至少一个用水洗涤所提取的海洋卵磷脂的步骤时,将提取的海洋卵磷脂溶解在有机溶剂混合物中。有时,这些方法的每一个还可以包括浓缩海洋卵磷脂并任选地与一种或多种油混合。
有时,所述一种或多种外源性抗氧化剂的加入量导致海洋卵磷脂制剂中外源性抗氧化剂的最终浓度为10mg/kg或更多,有时为100mg/kg或更多,有时为500mg/kg或更多,有时为1000mg/kg或更多,有时为1200mg/kg或更多,有时为1400mg/kg或更多,有时为1600mg/kg或更多,有时为2000mg/kg或更多,有时为2500mg/kg或更多,有时为3000mg/kg或更多,有时为4000mg/kg或更多。优选地,所述一种或多种外源性抗氧化剂包含生育酚。有时,所述一种或多种外源性抗氧化剂包含两种或更多种不同生育酚(例如α-生育酚、β-生育酚、γ-生育酚和δ-生育酚)的混合物。
本发明还提供了治疗或预防疾病或病症的方法,包括向受试者施用治疗有效量的如上文所公开的本发明海洋卵磷脂制剂中任一种的制剂。优选地,疾病或病症是心血管疾病、认知疾病、炎症、炎性疾病、关节炎、抑郁症或经前期综合征。在某些非限制性实施方案中,受试者患有心血管疾病、认知疾病、炎症、炎性疾病、关节炎、抑郁症或经前期综合征。在本发明的某些其它非限制性实施方案中,受试者患有胃肠道疾病或病症。胃肠道疾病和病症包括:克罗恩病或溃疡性结肠炎、消化性溃疡、胃溃疡、胃食管反流病(GERD)和肠易激综合征(IBS)等炎症性肠病。
本发明还提供降低施用于需要海洋卵磷脂的受试者的组合物的氧化状态的方法,包括施用所述组合物并将有效量的任何一种上述公开的海洋卵磷脂制剂共同施用于需要海洋卵磷脂的受试者。在某些非限制性实施方案中,受试者患有心血管疾病、认知疾病、炎症、炎性疾病、关节炎、抑郁症或经前期综合征。在本发明的某些其它非限制性实施方案中,受试者患有胃肠道疾病或病症。胃肠道疾病和病症包括:克罗恩病或溃疡性结肠炎、消化性溃疡、胃溃疡、胃食管反流病(GERD)和肠易激综合征(IBS)等炎症性肠病。
具体实施方案
本发明首次公开了含有一种或多种外源性抗氧化剂的海洋卵磷脂制剂。
术语“卵磷脂”是指含有1%w/w或更多种磷脂的脂质组合物。
术语“外源性抗氧化剂”是指至少一种天然或合成的抗氧化剂或其组合,其加入到海洋卵磷脂中,和/或加入到海洋卵磷脂的原料中,和/或在生产海洋卵磷脂的任何步骤期间,并且至少部分地存在于海洋卵磷脂制剂中。
如本文所用,术语“海洋卵磷脂制剂”和“制剂”或其任意的语言变体是可互换的。
天然抗氧化剂从天然来源分离或源自天然来源,例如但不限于:海洋来源(如鱼、鱼类部分、磷虾、鱿鱼、小虾(shrimp)或其他甲壳类动物)、植物来源(如大豆、向日葵、油菜籽、油菜(canola)、玉米、橄榄、迷迭香、茉莉、水果、草本、牛至属植物(origanum)、梅利莎(Melissa)、葡萄、人参、蔓越莓和茶)、微生物(野生发现的、发酵生长的或其他的)和动物来源(例如蛋、牛奶、羊毛、牛肉、猪油脂肪等)。
根据一个实施方案,从磷虾(磷虾油)、鱼或鱼部分、鱿鱼、小虾或其他甲壳类动物中提取海洋卵磷脂。
根据另一个实施方案,本发明的海洋卵磷脂制剂还包含油。任选地,所述油选自鱼油、藻油、植物油及其任何组合。任选地,油包含的ω3脂肪酸浓度为25%(w/w)或更高,有时为35%(w/w)或更高,有时为50%(w/w)或更高。
在本发明的一个实施方案中,海洋卵磷脂制剂含有的外源性抗氧化剂水平为10mg/kg或以上,有时为100mg/kg或以上,有时为500mg/kg或以上,有时为1000mg/kg或以上,有时为1200mg/kg或以上,有时为1400mg/kg或以上,有时为1600mg/kg或以上,有时为2000mg/kg或以上,有时为2500mg/kg或以上,有时为3000mg/kg或以上,有时为4000mg/kg或更多。
根据另一个实施方案,所述一种或多种外源性抗氧化剂选自:生育酚、生育三烯酚、抗坏血酸棕榈酸酯、抗坏血酸、迷迭香提取物、鼠尾草酸、多酚、酚类及其任意组合。多酚和/或酚类可以是天然来源的(例如,来自茶、葡萄酒或橄榄),合成来源的,或其混合物,并且可以包括:酚酸(没食子酸、鞣花酸、丹宁酸、咖啡酸、绿原酸、肉桂酸、阿魏酸和香豆素)、单宁、木质素、类黄酮亚类,其中包括黄酮醇(如槲皮素、高良姜素、山奈酚、杨梅酮、非瑟酮、异鼠李素、藿香黄酮醇(pachypodol)、鼠李秦素(rhamnazin)、芦丁、羟乙基云香甙(hydroxyethylrutoside))、黄酮(金合欢素(acacetin)、芹黄素、柯因(chrysin)、香叶木素、橘黄酮、木犀草素)、异黄酮、黄烷酮(橙皮苷、柚皮素、水飞蓟宾、圣草酚)、花青素(anthocyanidin)、黄烷醇(儿茶素、没食子儿茶素、表儿茶素、表没食子儿茶素、表没食子儿茶素没食子酸酯(EGCG)、原花青素(Proanthocyanidin)、芪、原花青素(proanthocyanidin)(或无色花青素(leucoanthocyanidin))、原矢车菊素(procyanidin)、茶黄素、茶红素黄酮醇、3-羟基黄烷酮(如二氢槲皮素、二氢山奈酚)、异黄酮(如染料木素、黄豆苷元、黄豆黄素)、矢车菊素(cyanidin)、飞燕草色素(delphinidin)、锦葵色素(malvidin)、天竺葵色素(pelargonidin)、芍药花色素(peonidin)、牵牛花色素(petunidin)、白藜芦醇、苯丙素、花青素脱氢聚酯型儿茶素(anthocyanidins dehydrotheasinensin)、聚酯型儿茶素醌(theasinensin quinone)、表茶黄棓灵(epitheaflagallin)、羟基茶黄素、前表茶黄棓灵(proepitheaflagallin)和羟基酪醇。优选地,所述一种或多种外源性抗氧化剂是不含任何另外的抗氧化剂的生育酚。优选地,所述一种或多种外源性抗氧化剂包含两种或更多种不同生育酚(例如α-生育酚和β-生育酚)的混合物。
根据本发明的另一个实施方案,海洋卵磷脂制剂中的TMAO水平为25mgN/100g或更少,有时15mgN/100g或更少,有时为10mgN/100g或更少,有时为7mgN/100g或更少,有时为5mgN/100g或更少,有时为5mgN/100g或更少,有时为3mgN/100g或更少,和有时为1mgN/100g或更少。
术语“内源性钙水平”或“内源性镁水平”是指从海洋卵磷脂生物质中提取而不添加天然或合成钙或镁的钙或镁水平。
在本发明的一个实施方案中,海洋卵磷脂制剂含有高的内源性钙水平,优选700mg/kg或更高,低水平的钠,优选1200mg/kg或更低,和/或低的TMA含量,优选5mgN/100g或更低。
根据本发明的另一个实施方案,海洋卵磷脂制剂中的内源性钙水平高于700mg/kg,有时高于1000mg/kg,有时高于1200mg/kg,有时高于2000mg/kg,有时高于3000mg/kg,和有时高于4000mg/kg。
根据本发明的另一个实施方案,海洋卵磷脂制剂中的钠水平低于1200mg/kg,有时低于1100mg/kg,有时低于1000mg/kg,有时低于900mg/kg,有时低于700mg/kg,和有时低于500mg/kg。根据本发明的另一个实施方案,海洋卵磷脂制剂中的钙水平高于钠水平;有时Ca/Na的比率大于1,有时大于2,有时比率大于3,有时比率大于4。
在本发明的一个实施方案中,储存至少4个月后,海洋卵磷脂制剂的TMA水平不会增加高于5mgN/100g,有时为4mgN/100g,有时为3mgN/100g,有时为1mgN/100g。在本发明的另一个实施方案中,在储存至少5个月,至少6个月,至少7个月,至少8个月,至少9个月,至少10个月,至少11个月,或至少一年后,TMA水平不会增加高于5mgN/100g,有时为4mgN/100g,有时为3mgN/100g,有时为1mgN/100g。
在本发明的一个优选实施方案中,在环境温度(20-30℃)下至少6个月的时间,或在40℃或更低至少3个月的时间内,海洋卵磷脂制剂的TMA水平不会增加高于5mgN/100g,优选4mgN/100g,更优选3mgN/100g,最优选1mgN/100g。
根据本发明的一个实施方案,海洋卵磷脂制剂含有高的内源性镁水平,为高于500mg/kg,有时高于750mg/kg,有时高于1000mg/kg,和有时高于2000mg/kg。
根据本发明的一个实施方案,海洋卵磷脂制剂含有低的游离胆碱水平,有时少于450mg/kg,有时少于300mg/kg,有时少于200mg/kg,和有时少于100mg/kg。
根据本发明的一个实施方案,海洋卵磷脂制剂含有低的甜菜碱水平,有时少于1000mg/kg或750mg/kg,有时少于500mg/kg或250mg/kg,有时少于50mg/kg,和有时少于10mg/kg。
根据本发明的一个实施方案,海洋卵磷脂制剂含有低的总氨基酸水平,有时少于0.3g/100g,有时少于0.1g/100kg,和有时少于0.05g/100g。
根据本发明的另一个实施方案,磷虾油制剂含有低水平的以下氨基酸:丙氨酸、精氨酸、天冬氨酸、胱氨酸、谷氨酸、甘氨酸、组氨酸、异亮氨酸、亮氨酸、赖氨酸、甲硫氨酸、鸟氨酸、苯丙氨酸、脯氨酸、丝氨酸、羟脯氨酸、苏氨酸、色氨酸、酪氨酸、缬氨酸。优选地,所述氨基酸之一的每一种的水平小于0.15g/100g或0.1g/100g,优选小于0.05g/100g,更优选小于0.04g/100g,甚至更优选小于0.02g/100g,最优选小于0.006g/100g。
根据本发明的另一个实施方案,海洋卵磷脂制剂包含至少2%(w/w)的磷脂,有时高于10%(w/w),有时高于25%(w/w),有时高于35%(w/w)磷脂,有时高于40%(w/w),有时高于45%(w/w),有时高于50%(w/w),和有时高于60%(w/w)。
根据本发明的另一个实施方案,海洋卵磷脂制剂包含至少3%(w/w)的EPA,有时高于5%(w/w)EPA,有时高于6%(w/w)EPA,有时高于8%(w/w)EPA,有时高于10%(w/w)EPA,和有时高于12%(w/w)EPA。根据本发明的另一个实施方案,海洋卵磷脂制剂包含至少2%(w/w)DHA,有时高于3%(w/w)DHA,有时高于5%(w/w)DHA,有时高于7%(w/w)DHA,和有时高于10%(w/w)DHA。
本发明的海洋卵磷脂制剂可以是流体油、粉末、颗粒、蜡、糊、油或水乳液形式,以及使其能够使用的任何其它形式。在本发明的另一方面,海洋卵磷脂制剂与营养、药物或保健组合物或功能食品或医疗食品结合使用或是其一部分。
本发明还提供了包含上述任一种海洋卵磷脂制剂的营养、药物或保健组合物或功能食品或医疗食品。
本文使用的医疗食品是特别配制的并且旨在用于具有不能通过单独的正常饮食满足的独特营养需要的疾病/病症的膳食管理。
本文使用的营养组合物可以是任何营养组合物,包括但不限于:人乳脂替代品、婴儿配方、成人配方、乳制品、奶粉、饮料、奶昔、冰淇淋、饼干、大豆产品、焙烤制品、糕点、面包、蛋糕、酱汁、汤、预制食品、冷冻食品、调味品、糖食、油、脂肪、人造黄油、涂抹食品、填充料、谷物、即食产品、婴儿食品、幼儿食品、棒(bar)、小吃、糖果和巧克力产品。
本文使用的功能性食品可以是任何功能性食品,包括但不限于乳制品、冰淇淋、饼干、大豆制品、焙烤制品、糕点、蛋糕和面包、即食产品、酱汁、汤、预制食品、冷冻食品、调味品、糖食、油和脂肪、人造黄油、涂抹食品、填充料、谷物、即食产品、饮料和奶昔、婴儿食品、棒、小吃、糖果和巧克力产品。
本文使用的保健组合物可以是任何保健品,其可以是可以被认为是食物或食物的一部分并提供医学或健康益处(包括预防和治疗疾病或病症)的任何物质。这种保健组合物包括但不限于:食品添加剂、食品补充剂、膳食补充剂、基因工程食品(例如蔬菜、草药产品和加工食品如谷物、汤和饮料)、兴奋性功能食品、临床营养产品、医用食品和药用食品(pharmafood)。膳食补充剂可以以软凝胶胶囊、片剂、糖浆和其它已知的膳食补充剂递送系统的形式递送。
药物或保健组合物可以是本领域通常使用的许多剂量递送形式中的任一种。适合于口服施用的药物组合物可以作为离散的剂量单位(例如丸剂、片剂、微丸、糖衣丸、胶囊或软凝胶)、作为粉剂或颗粒剂或作为溶液剂、混悬剂、糖浆剂或酏剂形式提供。
用于本发明组合物的合适的施用途径是口服、颊含、舌下、经由饲管的肠内、局部、透皮、皮下或肠胃外(包括皮下、肌内、静脉内和皮内)施用。在一个实施方案中,化合物经口服施用。
本发明还提供药物组合物,其中海洋卵磷脂制剂与(药学上)可接受的助剂和任选的其它治疗剂混合。助剂在与组合物的其它成分相容的意义上必须是“可接受的”,并且对其接收者无害。
在本发明的一个实施方案中,本发明的药物组合物还包含至少一种另外的药物活性剂。
本发明提供了制备本发明的海洋卵磷脂制剂的方法,其包括提取过程、任选洗涤和抗氧化剂富集。
在本发明的另一个方面,本发明提供本发明的海洋卵磷脂制剂,其用于降低CVD危险因子,和/或治疗或预防CVD,和/或改善患有CVD的受试者的病况和/或改善患有认知疾病或病症的受试者的病况,和/或治疗或预防认知疾病或病症,和/或治疗或预防炎症或炎性疾病和/或改善患有炎症或炎性疾病或病症的受试者的病况,和/或治疗或预防抑郁症和/或改善患有抑郁症的受试者的病况,和/或治疗或预防经前期综合症,和/或改善患有经前期综合征的受试者的病况。
在一个实施方案中,本发明提供了用于减轻体重、降低血压或心率和/或用于改善血清脂质谱(profile)的本发明制剂。
提取卵磷脂的阶段任选地通过向海洋生物质中加入一种或多种有机溶剂来形成卵磷脂提取物而进行。生物质可以是磷虾粉、鱼粉的形式,新鲜或冷冻的磷虾或鱼的形式,或新鲜或冷冻的磷虾或鱼通过烹饪和倾析处理除去一些含水量的形式。在制备生物质例如磷虾粉或鱼粉时,任选加入抗氧化剂。任选地,在磷虾或鱼粉生产的情况下,在干燥阶段之前、期间和/或之后加入这些抗氧化剂。任选地,通过离心、过滤、重力分离或其它方法将液相(含有溶于有机溶剂中的卵磷脂)与脱脂生物质分离。任选地,通过重复上述方法从生物质中提取与脱脂生物质一起留下的残留卵磷脂:向脱脂的生物质中加入一种或多种有机溶剂并通过相同的任选方法(即离心、过滤、重力分离等)分离液体。在进行再提取的情况下,将从提取和再提取获得的液相合并以形成最终的液相。
在选择过滤作为分离方法的情况下,可以通过在从其中除去第一液相之后简单地洗涤作为“滤饼”剩下的脱脂生物质进行重复提取。通过洗涤进行的所述再提取将再次通过使用一种或多种有机溶剂进行。从提取和再提取获得的滤液(即液相)合并形成最终的液相。
任选地通过加入水,任选地还加入有机溶剂,将水和有机溶剂与最终液相混合,洗涤最终液相。混合后,任选地通过重力进行分离或通过离心进行分离,形成两个不同的相:含有海洋卵磷脂的有机相和含有大部分水的第二相(即水相)。有机相可任选地用水和任选的有机溶剂以相同的程序洗涤。无论是否洗涤,最终液相任选进行蒸发阶段,以除去有机溶剂并获得卵磷脂。蒸发可以在减压下进行。
提取或再提取阶段期间溶剂与海洋生物质(溶剂体积与生物质重量)之比小于10:1,优选小于5:1,更优选小于4:1。
应该控制提取条件,并且可以任选地保持在10-60℃之间,优选在30-40℃之间,并且保持1分钟至10小时,优选保持1-3小时,更优选保持2-2.5小时。提取可以分批进行,例如在间歇反应器中,或任选地通过连续提取工艺进行。在连续提取系统如本领域已知的那些中,可以以并流或逆流模式进行连续提取。在连续提取中溶剂与海洋生物质的比例被认为是系统中两种料流的流量之比。
水洗阶段也可以任选地连续地进行。任选地,水和有机相可以通过在线混合器(in-line mixer)或通过CSTR或通过混合器-沉降器系统混合。混合的水-有机相可以通过连续或分批重力分离罐,或任选地通过连续离心分离。在连续洗涤的情况下,水、有机溶剂和最终液相之间的比率将被认为是三个料流中每一个的流量之间的比率。
有机溶剂任选地包含这样的有机溶剂,其任选地包含极性和非极性溶剂的混合物。极性溶剂可以包括以下的一种或多种:乙醇、甲醇、2-丙醇和丁醇。非极性溶剂可以包括以下的一种或多种:己烷、庚烷和石油醚。极性和非极性溶剂(体积与体积)之比优选为1:99-99:1,更优选为5:95-50:50,最优选为10:90-20:80。优选的溶剂混合物是己烷和乙醇混合物。
在洗涤阶段期间用于洗涤有机相(含有溶解在有机溶剂中的卵磷脂)的水相体积任选地小于最终液相体积的100%,有时小于最终液相的50%,有时小于最终液相体积的10%。
在蒸发后获得的卵磷脂任选进行水洗阶段,其中卵磷脂优选再溶解在有机溶剂中以形成有机相。加入水,任选地与有机溶剂一起,或任选地在其后加入到有机相中,与之一起混合,并任选地通过重力分离或离心与其分离。水洗阶段可任选地重复一次或几次。最终的海洋卵磷脂制剂将通过从洗涤的卵磷脂中去除溶剂,任选地通过蒸发有机溶剂,优选在减压下蒸发而获得。
进行水洗涤时形成有机相的卵磷脂和有机溶剂之间的比例有时是(卵磷脂重量与有机溶剂体积之比)1:1-1:40,有时为1:2-1:30,有时为1:3-1:10,有时1:5-1:8。
有机溶剂任选地包含这样的有机溶剂,其任选地包含极性和非极性溶剂的混合物。极性溶剂可包括:乙醇、甲醇、丁醇等。非极性溶剂可以来自以下的一种或多种:己烷、庚烷等。极性和非极性溶剂(体积与体积)之比优选为1:99-99:1,更优选为5:95-50:50,更优选为10:90-20:80。优选的溶剂混合物是己烷和乙醇混合物。
在水洗涤阶段用于洗涤有机相(含卵磷脂+有机溶剂)的水相体积小于有机相体积的100%,有时小于有机相体积的50%,有时小于有机相体积的40%,有时小于有机相体积的30%,有时小于有机相体积的20%,有时小于有机相体积的10%。
根据另一个实施方案,可以处理海洋卵磷脂以便将磷脂浓度增加至40%(w/w)或更高,时间为50%(w/w)或更高,有时为60%(w/w)或更高。可以使用溶剂进行磷脂浓缩阶段。浓缩的海洋卵磷脂可以任选地与一种或多种油混合以形成海洋卵磷脂制剂,其中磷脂浓度任选为30%(w/w)或更高,有时为40%(w/w)或更高,有时为50%(w/w)或更高。用于共混的一种或多种油可以任选地选自:鱼油、藻油、植物油或其任何组合。任选地,用于共混的一种或多种油可以包含25%(w/w)或更高,有时为35%(w/w)或更高,有时为50%(w/w)或更高的ω3脂肪酸浓度。任选地,ω3脂肪酸是EPA和/或DHA。用于共混的一种或多种油可以任选地呈甘油三酯形式、乙基酯形式、游离脂肪酸形式或其任何组合。外源性抗氧化剂可以在如下过程阶段的一个或多个中加入到海洋卵磷脂中:在其经历磷脂浓缩阶段之前,在磷脂浓缩阶段期间,在海洋卵磷脂与一种或多种油混合的阶段期间,加入到包含一种或多种油或其任何组合的海洋卵磷脂制剂中。
海洋卵磷脂样品中的三甲胺(TMA)水平由挪威的Nofima BioLab的外部实验室测试。根据Conway和Byrne的微扩散方法的修改版本在Conway盘中进行测量(E.J.Conway等人,1933;K.J.Obink 1955)。
海洋卵磷脂样品中的TMAO水平由挪威的Nofima BioLab的外部实验室测试。根据Conway和Byrne的微扩散方法的修改版本在Conway盘中进行测量(E.J.Conway等人,1933;K.J.Obink 1955)。
通过FOX分析测试氢过氧化物水平。在562nm处进行测量,其是铁-二甲酚橙复合物的吸光度(Gay 1999)。
丙二醛(MDA)水平通过改良的TBARS试验进行测试。通过HPLC(Fenaille 2001)或分光光度计定量硫代巴比妥酸-MDA加合物。
海洋卵磷脂样品中的磷脂(PL)含量由第三方实验室(Spectral Services)通过31P-NMR分析,或由HPTLC分析计算。通过用氯仿和甲醇溶液(95:5的体积比体积)溶解样品,使用含有水、甲醇、乙酸、丙酮和氯仿的洗脱液在HPTLC硅胶板上运行样品,然后用含有水、硫酸和无水硫酸铜的染色溶液染色该板,进行HPTLC分析。通过气相色谱(改性AOCS官方方法Ce 1b-89或改性AOCS Ce 1i-07)分析EPA和DHA含量。
通过加拿大POS Bio-sciences的ICP方法进行海洋卵磷脂样品中矿物质和金属含量的元素分析。
海洋卵磷脂样品中的胆碱和甜菜碱由德国的Eurofins Analytik GmbH使用LC-MS-MS分析。
根据参考方法ISO 13903:2005;EC 152/2009(F)和ISO 13904:2005;EC 152/2009(F),由Eurofins Analytik GmbH分析总氨基酸含量。
加速稳定性试验是药物和产品的标准的加速储存条件模型(“新药物和产品稳定性测试Q1A(R2)”,ICH协调三方指南,2003年2月)。
本文所用的术语百分比(%)与化合物的量和浓度结合使用,表示重量百分比。
实施例
实施例1:根据本发明的海洋卵磷脂制剂的制备
实施例1A.
通过向200克磷虾粉中加入800毫升溶剂并在约40℃下振荡约2小时来进行从磷虾粉中提取油。溶剂混合物分别含有体积比约为90:10的己烷和乙醇。使用Buchner真空系统从粉末中过滤溶剂(包括提取的油)。剩下作为“滤饼”的脱脂粉末用另外400毫升相同的溶剂混合物洗涤,以进一步提取留在脱脂粉末中的油。将所有滤液合并,并将溶剂在旋转蒸发器中减压蒸发,在约50℃的浴中进行约1小时,直至达到小于10毫巴的真空,并且油相中没有可见的沸腾。获得约50克油。
将50克所获得的油中的约30克溶解在约930毫升的溶剂混合物中,其中包括体积比如下的己烷、乙醇和水:87.1%己烷,9.7%乙醇,3.2%水。搅拌该溶液,使有机相和水相在分液漏斗中分离。向上部的有机相中加入相当于最终磷虾油重量0.14%的混合天然生育酚。之后,蒸发(上部)有机相的溶剂,以在旋转蒸发器中减压制备磷虾油,在约50℃的浴中进行约1小时,直至达到小于10毫巴的真空,并且油相中没有可见的沸腾。
所描述的过程导致磷虾油制剂包含:PL=25.8g/100g;EPA=8.2g/100g;DHA=4.8g/100g;TMAO<1mgN/100g。
实施例1B.
使用连续工业单元逆流地提取磷虾油。提取在约40℃下用溶剂混合物进行,所述溶剂混合物分别含有体积比约为90:10的己烷和乙醇。设定系统参数以确保300kg/h的磷虾粉和1140L/h的溶剂的流量。含有溶解油的溶剂通过重力从脱脂粉末中连续分离。在约50℃下减压蒸发溶剂。将400kg所接收的油溶解在约2748L包括己烷、乙醇和水的溶剂混合物中。搅拌该溶液,使有机相和水相分离。将(上部)有机相的溶剂蒸发,以减压生成磷虾油。
将得到的油用由己烷、乙醇和水组成的相同溶剂混合物进行第二次洗涤。
所描述的过程导致磷虾油制剂包含:PL=36.4g/100g;EPA=11.2g/100g;DHA=6.5g/100g;TMAO<1mgN/100g;游离胆碱=87.1mg/kg;甜菜碱<2mg/kg;Ca=1800mg/kg;Na=400mg/kg和以下的氨基酸组合物:
氨基酸 | g/100g |
丙氨酸 | <0.015 |
精氨酸 | <0.042 |
天冬氨酸 | <0.017 |
半胱氨酸 | <0.006 |
谷氨酸 | <0.021 |
甘氨酸 | <0.019 |
组氨酸 | <0.02 |
羟脯氨酸 | <0.05 |
异亮氨酸 | <0.035 |
亮氨酸 | <0.015 |
赖氨酸 | <0.014 |
甲硫氨酸 | <0.024 |
鸟氨酸 | <0.05 |
苯丙氨酸 | <0.031 |
脯氨酸 | <0.02 |
丝氨酸 | <0.016 |
苏氨酸 | <0.006 |
色氨酸 | <0.01 |
酪氨酸 | <0.023 |
缬氨酸 | <0.016 |
实施例2:海洋卵磷脂稳定性
商业海洋卵磷脂的稳定性根据ICH“新药物和产品Q1A的稳定性试验”指南的推荐条件进行评估。为了长期稳定性,将海洋卵磷脂在25±2℃/60%±5%RH下保存12个月,在加速条件下,海洋卵磷脂在40±2℃/75%±5%RH下保存。
在每个测试点,分析样品的过氧化值(PV)(根据美国药典<401>脂肪和固定油;EP药典5.0 2.5.5)和对茴香胺。(根据美国药典<401>脂肪和固定油的修改版本;EP药典5.02.5.36)
如表1和表2所示,测试的海洋卵磷脂的稳定性没有显示任何降低,因为PV和对茴香胺水平保持低于药典接受水平。海洋卵磷脂的这种公认的稳定性通常归因于卵磷脂中天然抗氧化剂的存在(例如磷虾油中的虾青素),并且是经常不向海洋卵磷脂中添加外源性抗氧化剂的原因。
表1:在25±2℃/60%±5%RH下海洋卵磷脂的稳定性数据
月 | 过氧化物值(meO2q/Kg) | 对茴香胺 |
0 | <0.2 | 3.5 |
3 | <0.2 | 6.0 |
6 | <0.2 | 7.5 |
9 | <0.2 | 2.6 |
12 | <0.2 | 5.3 |
表2:在40±2℃/75%±5%RH下海洋卵磷脂的稳定性数据
月 | PV(meqO2/Kg) | 对茴香胺 |
0 | <0.2 | 3.5 |
1 | <0.2 | 0.8 |
2 | <0.2 | 5.4 |
3 | <0.2 | 4.3 |
6 | <0.2 | 7.3 |
实施例3:在胃模型中本发明的海洋卵磷脂制剂与常规海洋卵磷脂相比的抗氧化性评分
在含有2mg/ml NaCl、3.2mg/ml HCl 37%和7mg/ml胃蛋白酶(Pepsine)的模拟胃液(SGF)中,在200μM抗坏血酸和50μM FeCl3作为氧化催化剂的情况下,将根据本发明的海洋卵磷脂制剂和常规海洋卵磷脂在37℃下摇动孵育180分钟。油的最终浓度为10mg/ml。在胃模型中孵育180分钟后分析过氧化标记物氢过氧化物(LOOH,通过Ferric-XylenolOrange Complex-FOX测定)和丙二醛(MDA-TBA2HPLC分析)。
结果总结在表3中,该结果表明海洋卵磷脂在体外胃模型条件下倾向于氧化,脂质过氧化产物形成混合物(LOOH和MDA)。
为了根据其在胃模型中的抗氧化性对油进行分级,开发了评分量表。通过以下方法将每个样品按增加的抗氧化性顺序分为0至4:3mM或以下的LOOH或MDA水平被认为是低的,每个都为油提供了2分的得分。大于3并低于10mM的LOOH或MDA水平被认为是中等,得分为1。10mM或以上的LOOH或MDA水平被认为是高的,并且得分为0。总抗氧化性评分计算为LOOH和MDA评分的总和,并显示于下表3中。
有趣的是,获得了油之间的显著差异。具体来说,向高TMAO海洋卵磷脂(>25mgNTMAO/100g磷虾油)中加入混合天然生育酚降低了氧化参数的水平,从而使抗氧化性评分从0增加到1-2。类似地,与TMAO水平高且没有加入生育酚的油(0抗性评分)相比,低TMAO水平导致油具有更高的抗性评分(1)。最重要的是,如本发明的海洋卵磷脂制剂的高抗性得分(4)所证明的,在低TMAO水平和存在生育酚之间获得协同效应。这种协同效应是意想不到的,特别是相对于出版物来说,其指出TMAO存在增强了生育酚的抗氧化活性。Ishikawa(1978)证实,在TMAO的存在下,生育酚活性得到提高,并导致对亚油酸甲酯的自氧化的抑制,而在没有TMAO的情况下观察到过氧化值的显著增加。
类似地,Ishikawa和Yuki(1975)证明了生育酚和TMAO之间在抑制在60℃黑暗中保持的猪油氧化方面的协同作用。
表3
*Cognis的Covi-OX;天然生育酚的混合物>700mg/g
评分:MDA;LOOH≤3microM–2点
MDA;LOOH>3和<10microM–1点
MDA;LOOH≥10microM-0点
实施例4:在胃模型中本发明的海洋卵磷脂制剂与常规海洋卵磷脂相比的ω3水平
含有超过1000mg/kg外源性混合天然生育酚和小于5mgN/100g TMAO的根据本发明的海洋卵磷脂制剂(磷虾油)和不含外源性抗氧化剂和超过30mgN/100g TMAO的常规海洋卵磷脂(磷虾油)在含有2mg/ml NaCl、3.2mg/ml HCl 37%和7mg/ml胃蛋白酶的模拟胃液(SGF)中以及200μM抗坏血酸和50μMFeCl3作为氧化催化剂的情况下,在37℃下摇动孵育180分钟。在胃模型中孵育180分钟后分析过氧化标记物氢过氧化物(LOOH,通过Ferric-Xylenol Orange Complex-FOX测定)和丙二醛(MDA-TBA2HPLC分析)。
结果表明,在商业海洋卵磷脂中,ω-3脂肪酸水平——EPA和DHA降低约15%。然而,根据本发明的海洋卵磷脂的检测显示胃模型孵育后EPA和DHA水平的降低低于5%。
实施例5:选择用于本发明制剂的抗氧化剂
A.优选的鱼油用抗氧化剂
如实施例2所示,海洋卵磷脂在其保质期内是稳定的,因此通常在卵磷脂中不加抗氧化剂。与海洋卵磷脂相反,已知鱼油易于氧化,因此需要加入抗氧化剂(R.J.Hamilton1998;P.K.J.P.Wandasundara等人)。
相信由于不同的抗氧化剂通过不同的机制起作用,不同抗氧化剂的组合将产生最好的抗氧化活性。通过将四种不同的抗氧化剂(混合天然生育酚、抗坏血酸棕榈酸酯、迷迭香提取物和D-生育酚)及其组合添加到鱼油(含21%w/w EPA和52%w/w DHA)并评估称为油稳定指数(OSI)的在加速模型中的油稳定性(基于AOCS官方方法Cd 12b-92),测试该假设。
油稳定性指数定义为在分析条件下获得氧化快速加速之前的时间长度。抗氧化性的测度通常称为诱导期。因此,较高的值预测有更长的稳定期。
实际上,如表4所示,三种抗氧化剂的混合物表现出最好的抗氧化活性,两种抗氧化剂的混合物提供中度抗氧化活性,生育酚单独仅提供最小的活性。
表4:添加到鱼油中的不同抗氧化剂组合的OSI结果
混合天然生育酚=来自Cognis的Covi-Ox;12.5%抗坏血酸棕榈酸酯=来自Vitablend的VitablendTM160IP
迷迭迭香提取物=来自Naturex的StabilEnhance OSR
B.在胃模型中富含虾青素的商业磷虾油制剂的抗氧化性评分
含有高浓度TMAO的常规磷虾油富含三种浓度的虾青素,并如实施例3所述在模拟胃液(SGF)中孵育。在180分钟后分析作为过氧化标记物的氢过氧化物(LOOH,由Ferric-Xylenol Orange Complex-FOX测定-参见上述方法)。
结果总结在表5中,该结果确认商业磷虾油在体外胃模型条件下倾向被氧化,脂质过氧化产物形成混合物;例如氢过氧化物(LOOH)。令人感兴趣的是,虽然实施例3的结果表明,抗氧化剂(生育酚)的添加提高了抗性评分,但是即使虾青素浓度增加10倍以上,通过虾青素富集仅获得LOOH水平的最小变化。这个结果是意想不到的,特别是考虑到使用其它模型证明虾青素与生育酚相比具有更好的抗氧化活性的出版物(Hama等人2012;Miki W1991)。
表5
C.本发明不同海洋卵磷脂制剂的抗氧化性评分
具有低TMAO水平的海洋卵磷脂与不同的抗氧化剂混合并在模拟胃液(SGF)中孵育。孵育180分钟后分析过氧化标记物氢过氧化物(LOOH,通过Ferric-Xylenol OrangeComplex-FOX测定)和丙二醛(MDA-TBA2 HPLC分析)。
表6中总结的结果表明,虽然所有的抗氧化剂都改善了胃模型中的抗氧化性评分(一个或两个点的升高),但只有含有生育酚的抗氧化剂导致氧化分数提高了3到4个点。令人感兴趣的是,如果生育酚是唯一添加的抗氧化剂,或者如果将生育酚作为抗氧化剂混合物的一部分加入,则抗氧化性评分是相当的。鉴于使用抗氧化剂混合物观察到的增加鱼油稳定性的优点,这一结果是出人意料的。
表6
Claims (39)
1.海洋卵磷脂制剂,其包含:
海洋卵磷脂;和
一种或多种外源性抗氧化剂,其中所述制剂具有的所述一种或多种外源性抗氧化剂的浓度为10mg/kg或更多。
2.根据权利要求1所述的制剂,其中所述一种或多种外源性抗氧化剂的浓度为1000mg/kg或更多。
3.根据权利要求1所述的制剂,其中所述一种或多种外源性抗氧化剂以有效减少胃肠道条件中的脂质过氧化的量提供。
4.根据前述权利要求任一项所述的制剂,其中所述制剂具有25mgN/100g或更少的三甲胺N-氧化物(TMAO)浓度。
5.根据权利要求4所述的的制剂,其中TMAO的浓度为5mgN/100g或更低。
6.根据前述权利要求任一项所述的制剂,其还包含油。
7.根据权利要求6所述的制剂,其中所述油选自鱼油、藻油、植物油及其组合。
8.根据权利要求7所述的制剂,其中所述油包含至少一种ω-3脂肪酸,其中所述油具有25%(w/w)或更高浓度的所述至少一种ω-3脂肪酸。
9.根据前述权利要求任一项所述的制剂,其中所述一种或多种外源性抗氧化剂包括至少一种生育酚。
10.根据前述权利要求任一项的制剂,其中所述一种或多种外源性抗氧化剂包括两种或更多种不同的生育酚的混合物。
11.根据前述权利要求任一项的制剂,其中所述海洋卵磷脂来自磷虾源或鱼源。
12.根据权利要求11所述的制剂,其中所述海洋卵磷脂来自磷虾源。
13.根据前述权利要求任一项所述的制剂,其中所述制剂具有高于700mg/kg的外源性钙浓度。
14.根据前述权利要求任一项所述的制剂,其中所述制剂具有低于1200mg/kg的钠浓度。
15.根据前述权利要求任一项所述的制剂,其中所述制剂具有5mgN/100g或更少的三甲胺(TMA)浓度。
16.根据前述权利要求任一项的制剂,其中在胃模型中孵育180分钟后,所述制剂中丙二醛(MDA)水平不超过6μmol/g。
17.根据前述权利要求任一项的制剂,其中在胃模型中孵育180分钟后,所述制剂中氢过氧化物(LOOH)水平不超过10μmol/g。
18.根据前述权利要求任一项所述的制剂,其中在胃模型中孵育180分钟后,磷脂、甘油三酯、脂肪酸、虾青素或任何其它活性成分的水平为孵育前其初始值的80%或更高。
19.一种营养组合物,其包含根据权利要求1-18任一项所述的制剂。
20.一种保健组合物,其包含根据权利要求1-18任一项所述的制剂。
21.一种药物组合物,其包含根据权利要求1-18任一项所述的制剂。
22.一种膳食补充剂组合物,其包含根据权利要求1-18任一项所述的制剂。
23.一种医用食品组合物,其包含根据权利要求1-18任一项所述的制剂。
24.制备包含海洋卵磷脂和外源性抗氧化剂的海洋卵磷脂制剂的方法,其包括:
将海洋生物质与至少一种有机溶剂混合;
将所述至少一种有机溶剂与脱脂生物质分离,得到含有所述至少一种有机溶剂和海洋卵磷脂的液相;
从液相中蒸发出至少一种有机溶剂;
获得海洋卵磷脂;和
在该方法的任何阶段加入一种或多种外源性抗氧化剂。
25.制备包含海洋卵磷脂和外源性抗氧化剂的海洋卵磷脂制剂的方法,其包括:
在生物质的制备过程中加入一种或多种外源性抗氧化剂;
将海洋生物质与至少一种有机溶剂混合;
将所述至少一种有机溶剂与脱脂生物质分离,得到含有所述至少一种有机溶剂和海洋卵磷脂的液相;
从液相中蒸发出至少一种有机溶剂并获得海洋卵磷脂。
26.根据权利要求24或25所述的方法,其还包括至少一个用水洗涤的步骤。
27.根据权利要求26所述的方法,其中当进行所述至少一个用水洗涤提取的海洋卵磷脂的步骤时,将提取的海洋卵磷脂溶解在有机溶剂混合物中。
28.根据权利要求24至27任一项所述的方法,其还包括浓缩所述海洋卵磷脂。
29.根据权利要求28所述的方法,其还包括将海洋卵磷脂与一种或多种油混合。
30.根据权利要求24至29任一项所述的方法,其中将所述一种或多种外源性抗氧化剂添加至10mg/kg或更高浓度的海洋卵磷脂制剂。
31.根据权利要求30所述的方法,其中将所述一种或多种外源性抗氧化剂添加至1000mg/kg或更高浓度的海洋卵磷脂制剂。
32.根据权利要求24至31任一项所述的方法,其中所述一种或多种外源性抗氧化剂包括生育酚。
33.根据权利要求24至31任一项所述的方法,其中所述一种或多种外源性抗氧化剂包括两种或更多种不同的生育酚的混合物。
34.治疗或预防心血管疾病、认知疾病、炎症、关节炎、抑郁或经前期综合征的方法,其包括:
向受试者施用治疗有效量的如权利要求1至23任一项所述的制剂。
35.一种降低施用于需要海洋卵磷脂的受试者的组合物的氧化状态的方法,其包括:
施用所述组合物;和
将有效量的如权利要求1-23任一项所述的海洋卵磷脂制剂共同施用给需要海洋卵磷脂的受试者。
36.根据权利要求34或35所述的方法,其中受试者患有胃肠道疾病或病症。
37.根据权利要求36所述的方法,其中所述胃肠道疾病或病症是炎症性肠病。
38.根据权利要求37所述的方法,其中所述炎症性肠病是克罗恩病或溃疡性结肠炎。
39.根据权利要求36所述的方法,其中所述胃肠道疾病或病症是消化性胃溃疡、胃食管反流病(GERD)或肠易激综合征(IBS)。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462062744P | 2014-10-10 | 2014-10-10 | |
US62/062,744 | 2014-10-10 | ||
PCT/IB2015/002114 WO2016055860A1 (en) | 2014-10-10 | 2015-10-08 | Marine lecithin preparations with enhanced oxidation resistance |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107105695A true CN107105695A (zh) | 2017-08-29 |
Family
ID=54783953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580066582.6A Pending CN107105695A (zh) | 2014-10-10 | 2015-10-08 | 具有增强的抗氧化性的海洋卵磷脂制剂 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20180125898A1 (zh) |
EP (1) | EP3203853A1 (zh) |
CN (1) | CN107105695A (zh) |
AU (1) | AU2015329663A1 (zh) |
CA (1) | CA2964067A1 (zh) |
WO (1) | WO2016055860A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112494499A (zh) * | 2020-12-14 | 2021-03-16 | 山东省科学院生物研究所 | 海洋磷脂作为有效成分在制备预防和/或治疗心脏疾病药物中的应用 |
CN113750216A (zh) * | 2021-10-22 | 2021-12-07 | 北京远胜达生物科技发展有限公司 | 一种抗衰老的化妆品或药物 |
CN114304375A (zh) * | 2015-02-11 | 2022-04-12 | 阿克海洋生物南极股份公司 | 脂质组合物 |
CN116370324A (zh) * | 2023-06-06 | 2023-07-04 | 成都普什制药有限公司 | 一种含有玻尿酸的抗氧化精华液及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019185888A1 (en) * | 2018-03-29 | 2019-10-03 | Dsm Ip Assets B.V. | Novel use of tocopherols |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004047554A1 (en) * | 2002-11-26 | 2004-06-10 | Phares Pharmaceutical Research N.V. | Marine lipid compositions |
CN1884287A (zh) * | 2005-06-22 | 2006-12-27 | 上海爱康精细化工有限公司 | 一种制备卵磷脂的方法 |
US20090074857A1 (en) * | 2003-10-22 | 2009-03-19 | Enzymotec Ltd. | Glycerophospholipids for the improvement of cognitive functions |
CN101686700A (zh) * | 2007-05-30 | 2010-03-31 | 雀巢产品技术援助有限公司 | 水包油乳剂及其用于延迟释放活性成分的用途 |
WO2010035013A1 (en) * | 2008-09-26 | 2010-04-01 | Omegatri As | Krill oil powder and krill oil tablets |
US20130059768A1 (en) * | 2011-09-02 | 2013-03-07 | Arctic Nutrition As | Lipid compositions with high dha content |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2288193T3 (es) * | 2001-07-27 | 2008-01-01 | NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. | Fosfolipidos naturales de origen marino que contienen flavonoides y fosfolipidos poliinsaturados y sus usos. |
FR2880538B1 (fr) * | 2005-01-07 | 2008-12-26 | Polaris Soc Par Actions Simpli | Composition cosmetique et cosmeceutique a base d'huiles de poissons, de phospholipides d'origine marine avec ou sans huile de pepins de franboise |
WO2010136900A2 (en) * | 2009-05-28 | 2010-12-02 | Aker Biomarine Asa | Methods of using krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders |
US20110223246A1 (en) * | 2010-03-10 | 2011-09-15 | Joar Opheim | Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source |
GB201009368D0 (en) * | 2010-06-04 | 2010-07-21 | Sana Pharma As | Dietary formulations |
-
2015
- 2015-10-08 WO PCT/IB2015/002114 patent/WO2016055860A1/en active Application Filing
- 2015-10-08 EP EP15805252.2A patent/EP3203853A1/en not_active Withdrawn
- 2015-10-08 CA CA2964067A patent/CA2964067A1/en not_active Abandoned
- 2015-10-08 CN CN201580066582.6A patent/CN107105695A/zh active Pending
- 2015-10-08 US US15/518,031 patent/US20180125898A1/en not_active Abandoned
- 2015-10-08 AU AU2015329663A patent/AU2015329663A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004047554A1 (en) * | 2002-11-26 | 2004-06-10 | Phares Pharmaceutical Research N.V. | Marine lipid compositions |
US20090074857A1 (en) * | 2003-10-22 | 2009-03-19 | Enzymotec Ltd. | Glycerophospholipids for the improvement of cognitive functions |
CN1884287A (zh) * | 2005-06-22 | 2006-12-27 | 上海爱康精细化工有限公司 | 一种制备卵磷脂的方法 |
CN101686700A (zh) * | 2007-05-30 | 2010-03-31 | 雀巢产品技术援助有限公司 | 水包油乳剂及其用于延迟释放活性成分的用途 |
WO2010035013A1 (en) * | 2008-09-26 | 2010-04-01 | Omegatri As | Krill oil powder and krill oil tablets |
US20130059768A1 (en) * | 2011-09-02 | 2013-03-07 | Arctic Nutrition As | Lipid compositions with high dha content |
Non-Patent Citations (1)
Title |
---|
YUKIHIRO ISHIKAWA ET AL: "Synergistic Effect of Trimethylamine Oxide on the Inhibition of the Autoxidation of Methyl Linoleate by δ-Tocopherol", 《AGRICULTURAL AND BIOLOGICAL CHEMISTRY》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114304375A (zh) * | 2015-02-11 | 2022-04-12 | 阿克海洋生物南极股份公司 | 脂质组合物 |
CN112494499A (zh) * | 2020-12-14 | 2021-03-16 | 山东省科学院生物研究所 | 海洋磷脂作为有效成分在制备预防和/或治疗心脏疾病药物中的应用 |
CN112494499B (zh) * | 2020-12-14 | 2022-01-28 | 山东省科学院生物研究所 | 海洋磷脂作为有效成分在制备预防和/或治疗心脏疾病药物中的应用 |
CN113750216A (zh) * | 2021-10-22 | 2021-12-07 | 北京远胜达生物科技发展有限公司 | 一种抗衰老的化妆品或药物 |
CN116370324A (zh) * | 2023-06-06 | 2023-07-04 | 成都普什制药有限公司 | 一种含有玻尿酸的抗氧化精华液及其制备方法 |
CN116370324B (zh) * | 2023-06-06 | 2023-08-15 | 成都普什制药有限公司 | 一种含有玻尿酸的抗氧化精华液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2015329663A1 (en) | 2017-04-27 |
EP3203853A1 (en) | 2017-08-16 |
WO2016055860A1 (en) | 2016-04-14 |
US20180125898A1 (en) | 2018-05-10 |
CA2964067A1 (en) | 2016-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220118064A1 (en) | Multi-supplement compositions | |
CN107105695A (zh) | 具有增强的抗氧化性的海洋卵磷脂制剂 | |
US9034399B2 (en) | Dietary compositions for promoting brain health | |
Halaby et al. | Protective and curative effect of garden cress seeds on acute renal failure in male albino rats | |
JP2006014730A (ja) | 食品 | |
JP2006298887A (ja) | 活性酸素除去剤、肌の弾力保持剤、抗酸化作用補助剤 | |
US20220211079A1 (en) | Omega-3 Beverage | |
Pagliaro et al. | Sustainably sourced olive polyphenols and omega-3 marine lipids: A synergy fostering public health | |
JP2017178914A (ja) | 脳機能改善及び向上のための組成物 | |
KR100614970B1 (ko) | 들깨박 추출물을 유효성분으로 함유하는 인지기능장애예방 및 개선용 조성물 | |
US10765712B2 (en) | Use of a composition for lowering cholesterol level in a mammal, a method for its preparation and a product and a food additive comprising said composition | |
RU2228673C1 (ru) | Пищевой продукт, содержащий антиоксидант из экстракта шлемника байкальского | |
KR101111390B1 (ko) | 토코페롤, 비타민c와 레시틴이 첨가된 기능성 커피믹서 및 그 제조방법 | |
Aispuro-Hernández et al. | Cactaceae plants as sources of active bioavailable phytochemicals | |
RU2602608C1 (ru) | Функциональные продукты питания и способ их получения | |
Marwa et al. | Using some beetroot products to improve some parameters in anemic rats induced by phenylhydrazine | |
KR20240046305A (ko) | 복합 보충제 조성물 | |
Murage | Increasing the consumption of essential long chain fatty acids through fortification of yoghurt with Omega-3 pufa from Nile perch oil | |
TW201529079A (zh) | 龍葵萃取物用於降低體脂肪、體重及治療肥胖性肝炎 | |
KR20130038737A (ko) | 소장 지방흡수율 억제 효능이 있는 수수추출물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180524 Address after: Norway lussac Applicant after: AKER BIOMARINE AS Address before: Israel Migdal Emek Applicant before: Enzymotec Ltd. |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170829 |